Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Pharmacovigilance01:19

Pharmacovigilance

838
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
838
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

264
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
264
Clinical Trials01:16

Clinical Trials

6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.7K
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

736
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
736
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

129
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
129

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From model validation to policy resilience: stress testing healthcare systems with AI and cross-sectorial methodology.

Expert review of pharmacoeconomics & outcomes research·2026
Same author

Patients' Preferences for Surgical Procedures in Hidradenitis Suppurativa: A Discrete Choice Experiment.

The patient·2026
Same author

Vascular Access Surgery Timing: A Prospective European Cohort Study in Elderly Patients with ESKD.

Kidney360·2026
Same author

Medication adherence research: expert perspectives on key HEOR trends for 2026.

Expert review of pharmacoeconomics & outcomes research·2026
Same author

Prevention, artificial intelligence, and mathematics in health economics: a framework for dynamic value modeling under long-term uncertainty.

Expert review of pharmacoeconomics & outcomes research·2026
Same author

Clinical and economic impact of deep learning-enhanced opportunistic osteoporosis screening using chest radiographs with and without the osteoporosis self-assessment tool for Asians (OSTA).

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Different Clinical Questions Need Different Estimands.

Therapeutic innovation & regulatory science·2026
Same journal

Medicinal Chemistry Perspectives on Drug Repurposing: Innovative Approaches and Therapeutic Breakthrough.

Therapeutic innovation & regulatory science·2026
Same journal

Understanding the Added Value of Action Limits for QTL Monitoring.

Therapeutic innovation & regulatory science·2026
Same journal

Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

Therapeutic innovation & regulatory science·2026
Same journal

Validation of the Ontario Protocol Assessment Level (OPAL) Tool for Assessing Clinical Trial Complexity and Supporting Workforce Planning in the Italian Clinical Research Context.

Therapeutic innovation & regulatory science·2026
Same journal

The Effect of Covariate Adjustment for Cox Regression in Cardiovascular Outcome Trials.

Therapeutic innovation & regulatory science·2026
See all related articles

Related Experiment Video

Updated: Jul 6, 2025

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure
15:18

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure

Published on: July 30, 2009

18.2K

Pediatric Market Access: A Qualitative Study.

Lieke Maas1, Angelika Joos2, Mickael Hiligsmann3

  • 1Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, P.O Box 616, 6200 MD, Maastricht, The Netherlands. lieke.maas@maastrichtuniversity.nl.

Therapeutic Innovation & Regulatory Science
|January 3, 2024
PubMed
Summary
This summary is machine-generated.

Navigating pediatric drug market access requires addressing regulatory and reimbursement hurdles. Harmonizing requirements and implementing country-specific pricing models can improve patient access to essential medicines.

Keywords:
Market accessPediatric medicinesPediatric regulationPediatricsReimbursement

More Related Videos

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.4K
Assessment of the Efficacy of An Osteopathic Treatment in Infants with Biomechanical Impairments to Suckling
07:11

Assessment of the Efficacy of An Osteopathic Treatment in Infants with Biomechanical Impairments to Suckling

Published on: February 5, 2019

9.0K

Related Experiment Videos

Last Updated: Jul 6, 2025

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure
15:18

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure

Published on: July 30, 2009

18.2K
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.4K
Assessment of the Efficacy of An Osteopathic Treatment in Infants with Biomechanical Impairments to Suckling
07:11

Assessment of the Efficacy of An Osteopathic Treatment in Infants with Biomechanical Impairments to Suckling

Published on: February 5, 2019

9.0K

Area of Science:

  • Pharmaceutical Sciences
  • Health Policy
  • Regulatory Affairs

Background:

  • Pediatric drug development faces unique regulatory and market access challenges.
  • Current European market access pathways for pediatric medicines are complex and fragmented.

Purpose of the Study:

  • To analyze current pediatric medicine (PM) regulation and market access requirements in Europe.
  • To propose solutions for mitigating challenges in pediatric market access.

Main Methods:

  • Qualitative study involving 22 semi-structured interviews with diverse stakeholders (industry, regulators, HTA bodies, clinicians, academia).
  • Interviews covered pediatric research, regulatory/reimbursement processes, challenges, and solutions across the Netherlands, Germany, UK, and France.
  • Thematic analysis using Atlas.ti 9 to identify key factors for facilitating pediatric market access.

Main Results:

  • Significant heterogeneity exists in European Medicines Agency (EMA) and Health Technology Assessment (HTA) approval requirements.
  • Germany offers direct reimbursement post-approval, while other countries require additional steps, causing delays.
  • Facilitating factors include multi-stakeholder collaboration, transparency, patient involvement, real-world evidence, and tailored clinical trial designs.
  • Country-specific pricing models and pediatric incentives are crucial for innovation and timely patient access.

Conclusions:

  • Differences in regulatory and reimbursement approval processes create barriers for pediatric medicines in Europe.
  • International variations in pricing and reimbursement procedures necessitate strategic approaches to optimize pediatric market access.